Portal de Periódicos da CAPES

US Multicenter Experience With the Wingspan Stent System for the Treatment of Intracranial Atheromatous Disease

2007; Lippincott Williams & Wilkins; Volume: 38; Issue: 3 Linguagem: Inglês

10.1161/01.str.0000257963.65728.e8

1524-4628

David Fiorella, Elad I. Levy, Aquilla S Turk, Felipe C. Albuquerque, David Niemann, Beverly Aagaard‐Kienitz, Ricardó A. Hanel, Henry H. Woo, Peter A. Rasmussen, L. Nelson Hopkins, Thomas J. Masaryk, Cameron G. McDougall,

Acute Ischemic Stroke Management

Background and Purpose— The current report details our initial periprocedural experience with Wingspan (Boston Scientific/Target), the first self-expanding stent system designed for the treatment of intracranial atheromatous disease. Methods— All patients undergoing angioplasty and stenting with the Gateway balloon–Wingspan stent system were prospectively tracked. Results— During a 9-month period, treatment with the stent system was attempted in 78 patients (average age, 63.6 years; 33 women) with 82 intracranial atheromatous lesions, of which 54 were ≥70% stenotic. Eighty-one of 82 lesions were successfully stented (98.8%) during the first treatment session. In 1 case, the stent could not be delivered across the lesion; the patient was treated solely with angioplasty and stented at a later date. Lesions treated involved the internal carotid (n=32; 8 petrous, 10 cavernous, 11 supraclinoid segment, 3 terminus), vertebral (n=14; V4 segment), basilar (n=14), and middle cerebral (n=22) arteries. Mean±SD pretreatment stenosis was 74.6±13.9%, improving to 43.5±18.1% after balloon angioplasty and to 27.2±16.7% after stent placement. Of the 82 lesions treated, there were 5 (6.1%) major periprocedural neurological complications, 4 of which ultimately led to patient death within 30 days of the procedure. Conclusions— Angioplasty and stenting for symptomatic intracranial atheromatous disease can be performed with the Gateway balloon–Wingspan stent system with a high rate of technical success and acceptable periprocedural morbidity. Our initial experience indicates that this procedure represents a viable treatment option for this patient population.